Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tristetraprolin expression by keratinocytes protects against skin carcinogenesis
Assiya Assabban, Ingrid Dubois-Vedrenne, Laurye Van Maele, Rosalba Salcedo, Brittany L. Snyder, Lecong Zhou, Abdulkader Azouz, Bérengère de Toeuf, Gaëlle Lapouge, Caroline La, Maxime Melchior, Muriel Nguyen, Séverine Thomas, Si Fan Wu, Wenqian Hu, Véronique Kruys, Cédric Blanpain, Giorgio Trinchieri, Cyril Gueydan, Perry J. Blackshear, Stanislas Goriely
Assiya Assabban, Ingrid Dubois-Vedrenne, Laurye Van Maele, Rosalba Salcedo, Brittany L. Snyder, Lecong Zhou, Abdulkader Azouz, Bérengère de Toeuf, Gaëlle Lapouge, Caroline La, Maxime Melchior, Muriel Nguyen, Séverine Thomas, Si Fan Wu, Wenqian Hu, Véronique Kruys, Cédric Blanpain, Giorgio Trinchieri, Cyril Gueydan, Perry J. Blackshear, Stanislas Goriely
View: Text | PDF
Research Article Inflammation Oncology

Tristetraprolin expression by keratinocytes protects against skin carcinogenesis

  • Text
  • PDF
Abstract

Cancer is caused primarily by genomic alterations resulting in deregulation of gene regulatory circuits in key growth, apoptosis, or DNA repair pathways. Multiple genes associated with the initiation and development of tumors are also regulated at the level of mRNA decay, through the recruitment of RNA-binding proteins to AU-rich elements (AREs) located in their 3′-untranslated regions. One of these ARE-binding proteins, tristetraprolin (TTP; encoded by Zfp36), is consistently dysregulated in many human malignancies. Herein, using regulated overexpression or conditional ablation in the context of cutaneous chemical carcinogenesis, we show that TTP represents a critical regulator of skin tumorigenesis. We provide evidence that TTP controlled both tumor-associated inflammation and key oncogenic pathways in neoplastic epidermal cells. We identify Areg as a direct target of TTP in keratinocytes and show that EGFR signaling potentially contributed to exacerbated tumor formation. Finally, single-cell RNA-Seq analysis indicated that ZFP36 was downregulated in human malignant keratinocytes. We conclude that TTP expression by epidermal cells played a major role in the control of skin tumorigenesis.

Authors

Assiya Assabban, Ingrid Dubois-Vedrenne, Laurye Van Maele, Rosalba Salcedo, Brittany L. Snyder, Lecong Zhou, Abdulkader Azouz, Bérengère de Toeuf, Gaëlle Lapouge, Caroline La, Maxime Melchior, Muriel Nguyen, Séverine Thomas, Si Fan Wu, Wenqian Hu, Véronique Kruys, Cédric Blanpain, Giorgio Trinchieri, Cyril Gueydan, Perry J. Blackshear, Stanislas Goriely

×

Figure 2

TTP expressed by keratinocytes controls skin tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
TTP expressed by keratinocytes controls skin tumorigenesis.
Zfp36-V5 and...
Zfp36-V5 and Zfp36fl/fl mice were treated for 3 days with TPA or acetone on shaved back skin (A). Zfp36ΔDC, Zfp36ΔM, Zfp36ΔEP mice and their littermate controls (Zfp36fl/fl) were topically treated on back skin with DMBA/TPA for 12 to 20 weeks and monitored every week for tumor formation. The experiment was stopped when the tumors reached > 10 mM (B–E). (A) Ratio of V5-expressing skin cells in each condition analyzed by flow cytometry: macrophages, neutrophils, DCs, and epithelial cells (keratinocytes). Data are shown as percentage of the initial population (mean ± SEM, n = 6, representative of 2 experiments). (B) Kaplan-Meier plot of DMBA/TPA-treated mice depicting papilloma-free state after TPA promotion (n = 4–42, pool of 6 experiments). (C) Tumor burdens of Zfp36fl/fl, Zfp36ΔEP, Zfp36ΔM, and Zfp36ΔDC back skins. (D) Kinetics of cell infiltration in total back skin from Zfp36ΔEP mice: neutrophils and IL-17A–producing γδT cells among CD45+ cells are shown by intracellular protein staining. Results are given as mean ± SEM (n = 4–27, pool of 4 experiments). Gating strategy for flow cytometry is presented in Supplemental Figures 1 and 2. (E) Skin samples, including tumors, from Zfp36ΔEP mice and their littermates were collected for analysis of transcript levels by qPCR at 12 weeks of DMBA/TPA treatment. Results are expressed as relative to the Zfp36fl/fl mock group, which was arbitrarily set to 1 (mean ± SEM, n = 7). Statistical significance (*P < 0.05, **P < 0.01, ****P < 0.0001) was assessed by 2-tailed Mann-Whitney test (A and E), by Mantel-Cox log rank test and pairwise comparisons indicating differences between deficient mice compared with their controls (B) or by the 1-way ANOVA test with Bonferroni’s correction compared with the Zfp36fl/fl group (D). TTP, tristetraprolin; DMBA, 7,12-dimethylbenz[a]anthracene; TPA, 12-0-tetradecanoylphorbol-13-acetate.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts